Yale University

Protein ice cream company wins 2024 Rice Business Plan Competition

Retrieved on: 
Monday, April 8, 2024
Friends, Ulcer, University, Obstructive sleep apnea, Rice University, Entrepreneurship, Bacteria, Deformity, Love, Harvard University, Chevron Corporation, RWTH Aachen University, Chemical engineering, Reiss, Podiatry, University of Houston, Greater Houston, Foot, TiE, Mentorship, Northwestern University, Rice, University of California, Berkeley, WRX, Carnegie Mellon University, Yale University, University of Kansas, EY, Tulane University, Ice cream, Michigan State University, Johns Hopkins University, Heart, Intuitive Machines

HOUSTON, April 8, 2024 /PRNewswire/ -- Ice cream company Protein Pints took home the grand prize at the 2024 Rice Business Plan Competition (RBPC) April 6 as the best student ventures from top universities across the world competed for prizes in front of nearly 350 angel, venture capital and corporate investors and members of the business community.

Key Points: 
  • HOUSTON, April 8, 2024 /PRNewswire/ -- Ice cream company Protein Pints took home the grand prize at the 2024 Rice Business Plan Competition (RBPC) April 6 as the best student ventures from top universities across the world competed for prizes in front of nearly 350 angel, venture capital and corporate investors and members of the business community.
  • The best student ventures from top universities across the world competed in the 2024 Rice Business Plan Competition.
  • Hosted annually by the Rice Alliance for Technology and Entrepreneurship and Rice University's Jones Graduate School of Business , the RBPC is the world's largest and richest student startup competition.
  • Protein Pints is a high-protein, low-sugar, ice cream product designed for people who would benefit from having access to a functional ice cream and/or better tasting and more enjoyable protein options.

Paralyzed Veterans of America to Honor L'Oréal USA with PVA Disability Innovation Award at Igniting Change Gala on April 12

Retrieved on: 
Monday, April 8, 2024
Storm, Astronaut, Research, Gordon H. Mansfield, Microsoft, Penske Truck Leasing, Employment, Organization, Veteran, Woman, Yale University, Maybelline, Beauty, Target, Target Corporation, Communication, University, PVA, Paralyzed Veterans of America, Stanford University, Human, TriWest Healthcare Alliance, Marketing, NASA, Penske Automotive Group, Microsoft Teams, Disability, Sport, Government, Hand, Hospital

WASHINGTON, April 8, 2024 /PRNewswire/ -- On Friday, April 12, Paralyzed Veterans of America will host its Igniting Change Gala and present the PVA Disability Innovation Award to L'Oréal USA, the largest subsidiary of the L'Oréal Groupe, the worldwide beauty leader.

Key Points: 
  • WASHINGTON, April 8, 2024 /PRNewswire/ -- On Friday, April 12, Paralyzed Veterans of America will host its Igniting Change Gala and present the PVA Disability Innovation Award to L'Oréal USA, the largest subsidiary of the L'Oréal Groupe, the worldwide beauty leader.
  • L'Oréal USA was chosen as it has been a leader committed to driving greater inclusion in the beauty industry.
  • L'Oréal USA actively supports the veteran community through various community initiatives led by VALOR, its employee-led resource group dedicated to veterans.
  • "PVA commends L'Oréal for its important contributions to disability innovation and inclusion, as they exemplify the spirit of our organization's own history of innovation."

Calvin Mew (PMD 1984) to Serve as Harvard Business School Club of New York's Next President

Retrieved on: 
Friday, April 5, 2024
Woman, Peeters, Domestic violence, National Council, Harvard Business School, Human, Columbia University, Treasurer, Teachers College, Columbia University, Union Theological Seminary, MBA, Center Against Domestic Violence, Small business, Club, Council, PMD, Advertising, Bozell, Yale University, Osborne Association, Management

NEW YORK, April 5, 2024 /PRNewswire/ -- The Harvard Business School Club of New York ( HBSCNY ) is pleased to announce that Calvin Mew (PMD 1984) will serve as President beginning July 1, 2024.

Key Points: 
  • NEW YORK, April 5, 2024 /PRNewswire/ -- The Harvard Business School Club of New York ( HBSCNY ) is pleased to announce that Calvin Mew (PMD 1984) will serve as President beginning July 1, 2024.
  • Mew will succeed outgoing President, Clare Peeters (MBA 2000), after three years of exceptional leadership.
  • Mew has been an integral part of the Club for over two decades.
  • Besides Harvard Business School, Mew was educated at Yale University, Union Theological Seminary and Columbia University.

SPEVIGO® approved for expanded indications in China and the US

Retrieved on: 
Tuesday, March 19, 2024
Arthralgia, Urinary tract infection, Uncertainty, Human, NMPA, Psoriasis, Disease, Multiple organ dysfunction syndrome, Incidence, Risk, GPP, Boehringer Ingelheim, Patient, Ageing, Executive officer, Immunoglobulin G, Anxiety, Doctor of Philosophy, MD, Quality of life, Flare, Injection site reaction, Clinical trial, Skin, Fever, Immune system, Pain, Itch, Food, FDA, Yale University, Fear

In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.

Key Points: 
  • In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.
  • “Until now, people living with GPP have not had any approved options to treat their disease,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, Yale University and Central Connecticut Dermatology.
  • “Experiencing GPP can be mentally and physically devastating, leaving those affected with uncertainty and fear of the next episode.
  • Therefore, expanding the treatment of GPP is a critical step towards addressing patients’ needs.”

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Neurology, University of Pennsylvania, Sarcoma, Cardiology, Ivy League, Protocol, University, Rheumatology, Dermatology, Infection, Harvard University, FSD, Melanoma, CMO, Vaccine, FDA, GU, Women's health, Yale University, Pharmaceutical industry

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).

Key Points: 
  • MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).
  • “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Her expertise encompasses the development of Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, and effective leadership of medical affairs teams.
  • “Dr.

Cambridge Savings Bank Supports the Expansion of Fair Haven Community Health Care with Loans Totaling Over $26 Million

Retrieved on: 
Thursday, April 4, 2024
Professional Services, Health, Hospitals, Other Health, Finance, Banking, Community, Savings bank, Dental care, Organization, Patient, History, CSB, CHC, Senior, Treasury management, Pediatrics, Pharmacy, Yale University, Corporation

Cambridge Savings Bank (CSB), a full-service mutual bank with a customer-first approach and over $6 billion in assets, today announced that its Corporate Banking team has provided Fair Haven Community Health Care (Fair Haven CHC) with a combined $26.1 million in loans to support its expansion.

Key Points: 
  • Cambridge Savings Bank (CSB), a full-service mutual bank with a customer-first approach and over $6 billion in assets, today announced that its Corporate Banking team has provided Fair Haven Community Health Care (Fair Haven CHC) with a combined $26.1 million in loans to support its expansion.
  • Based in New Haven, Connecticut, Fair Haven CHC provides low-income families with accessible, high-quality medical and dental care, regardless of their ability to pay.
  • With 20 locations including 12 satellite centers at local greater New Haven schools, Fair Haven CHC currently serves over 34,000 patients across a wide range of primary and specialty care services.
  • “Cambridge Savings Bank's community-focused approach and clear understanding of our mission have made the bank an invaluable ally in our expansion efforts.

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Manifest Technologies Emerges From Stealth With Strategic Investors and Prepares for Next Development Stage of AI-Powered Precision Neuroscience

Retrieved on: 
Thursday, March 28, 2024
Neurology, Biotechnology, Pharmaceutical, Managed Care, Health, Artificial Intelligence, Health Technology, Technology, Entrepreneurship, Psychiatry, Yale University, Associate, Partnership, Myenteric plexus, Patient, CNS, Neuroimaging, Research, DSM-IV codes, Dartmouth College, AI, Psychology, Yale School of Medicine, NIH, Johnson & Johnson, Drug development, CMO, Map

Today, over one billion people on the planet suffer from some form of a brain disorder, with an estimated economic burden of as much as $8.5 trillion per year.

Key Points: 
  • Today, over one billion people on the planet suffer from some form of a brain disorder, with an estimated economic burden of as much as $8.5 trillion per year.
  • There is an urgent unmet need for more rapid and precise development of treatments that are ultimately delivered to the right person at the right time.
  • Recent acquisitions in the neuroscience space highlight the need for tools that can optimize clinical trials and drive more efficient drug development based on precise neural targets.
  • Manifest is actively working with Johnson & Johnson to deploy its solutions across several programs.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Palliser Appoints Former Elliott Partner Steve Kasoff as Chairman of Palliser US

Retrieved on: 
Wednesday, March 20, 2024
Other Professional Services, Asset Management, Professional Services, Finance, Elliott Investment Management, Deutsch, Risk, Business, Capital, Management, University, ABS, CDO, Retirement, Yale University

Palliser Capital, a global multi-strategy investment firm, announced today that former Elliott Management Equity Partner and Senior Portfolio Manager, Steve Kasoff, joined Palliser on 1 March 2024 as Chairman of Palliser Capital US.

Key Points: 
  • Palliser Capital, a global multi-strategy investment firm, announced today that former Elliott Management Equity Partner and Senior Portfolio Manager, Steve Kasoff, joined Palliser on 1 March 2024 as Chairman of Palliser Capital US.
  • Steve spent 17 years at Elliott Management where he was responsible for the firm’s global investments in structured credit, real estate, ABS, CDOs, and the firm’s macro strategies.
  • Prior to joining Elliott in 2003, Steve spent a number of years as a Director at Deutsche Bank’s CDO Group.
  • Steve Kasoff: “Palliser was the obvious place for me to build the next phase of my career.